JP2021522783A5 - - Google Patents

Info

Publication number
JP2021522783A5
JP2021522783A5 JP2020560827A JP2020560827A JP2021522783A5 JP 2021522783 A5 JP2021522783 A5 JP 2021522783A5 JP 2020560827 A JP2020560827 A JP 2020560827A JP 2020560827 A JP2020560827 A JP 2020560827A JP 2021522783 A5 JP2021522783 A5 JP 2021522783A5
Authority
JP
Japan
Prior art keywords
sequence
protein
nonviral
abp
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560827A
Other languages
English (en)
Japanese (ja)
Other versions
JP7506405B2 (ja
JP2021522783A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030198 external-priority patent/WO2019213257A1/en
Publication of JP2021522783A publication Critical patent/JP2021522783A/ja
Publication of JP2021522783A5 publication Critical patent/JP2021522783A5/ja
Priority to JP2024093050A priority Critical patent/JP7832700B2/ja
Application granted granted Critical
Publication of JP7506405B2 publication Critical patent/JP7506405B2/ja
Priority to JP2026031877A priority patent/JP2026083211A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560827A 2018-05-01 2019-05-01 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法 Active JP7506405B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024093050A JP7832700B2 (ja) 2018-05-01 2024-06-07 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法
JP2026031877A JP2026083211A (ja) 2018-05-01 2026-02-27 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862665080P 2018-05-01 2018-05-01
US62/665,080 2018-05-01
PCT/US2019/030198 WO2019213257A1 (en) 2018-05-01 2019-05-01 Lentiviral-based vectors and related systems and methods for eukaryotic gene editing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024093050A Division JP7832700B2 (ja) 2018-05-01 2024-06-07 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法

Publications (3)

Publication Number Publication Date
JP2021522783A JP2021522783A (ja) 2021-09-02
JP2021522783A5 true JP2021522783A5 (cg-RX-API-DMAC7.html) 2022-04-01
JP7506405B2 JP7506405B2 (ja) 2024-06-26

Family

ID=66676890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020560827A Active JP7506405B2 (ja) 2018-05-01 2019-05-01 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法
JP2024093050A Active JP7832700B2 (ja) 2018-05-01 2024-06-07 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法
JP2026031877A Pending JP2026083211A (ja) 2018-05-01 2026-02-27 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024093050A Active JP7832700B2 (ja) 2018-05-01 2024-06-07 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法
JP2026031877A Pending JP2026083211A (ja) 2018-05-01 2026-02-27 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法

Country Status (6)

Country Link
US (2) US12398182B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788155A1 (cg-RX-API-DMAC7.html)
JP (3) JP7506405B2 (cg-RX-API-DMAC7.html)
AU (2) AU2019262029B2 (cg-RX-API-DMAC7.html)
CA (1) CA3098137A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019213257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019213257A1 (en) 2018-05-01 2019-11-07 Wake Forest University Health Sciences Lentiviral-based vectors and related systems and methods for eukaryotic gene editing
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) * 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CN110819707B (zh) * 2019-11-24 2023-07-18 中南大学湘雅医院 一种针对多种来源细胞样本中内部核糖体结合位点元件的高通量鉴定方法
WO2021142343A1 (en) * 2020-01-09 2021-07-15 The Regents Of The University Of California Targeting transfer rna for the suppression of nonsense mutations in messenger rna
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
JP2023550381A (ja) * 2020-11-19 2023-12-01 ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ 真核生物遺伝子編集のためのベクター、システムおよび方法
EP4277647A4 (en) * 2021-01-12 2025-03-19 University of Massachusetts Allele-specific inactivation of mutant HTT by gene editing of coding single nucleotide polymorphisms
WO2022165262A1 (en) * 2021-01-28 2022-08-04 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
CA3206732A1 (en) * 2021-02-12 2022-08-18 Baisong Lu Engineered extracellular vesicles and their uses
WO2022216536A1 (en) * 2021-04-06 2022-10-13 Animatus Biosciences, Inc. Selective expression of mrnas in cardiomyocytes without cardiac fibroblast stimulation
US20240366790A1 (en) * 2021-05-21 2024-11-07 Aarhus Universitet Lentivirus-derived nanoparticles comprising crispr/cas9 ribonucleoprotein complexes
JP7125727B1 (ja) 2021-09-07 2022-08-25 国立大学法人千葉大学 核酸配列改変用組成物および核酸配列の標的部位を改変する方法
AU2023232138A1 (en) * 2022-03-08 2024-09-26 Wake Forest University Health Sciences Compositions, systems and methods for eukaryotic gene editing
CN116218906A (zh) * 2023-01-31 2023-06-06 安可来(重庆)生物医药科技有限公司 一种rna编辑器表达质粒、外泌体适配子融合表达质粒以及一种靶向基因rna编辑方法
WO2025242168A1 (en) * 2024-05-22 2025-11-27 Nanjing Legend Biotech Co., Ltd. Methods of making cells expressing an engineered receptor
CN118903442A (zh) * 2024-07-19 2024-11-08 上海佰炼生物医药科技有限公司 基于PP7 RNA茎环结构的高效VLP载体及其用于递送mRNA
CN119662735A (zh) * 2024-10-10 2025-03-21 上海佰炼生物医药科技有限公司 一种基于核定位信号和pp7 rna茎环结构的重组质粒及其载体系统和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004225520A1 (en) 2003-03-25 2004-10-14 Stratagene DNA polymerase fusions and uses thereof
GB0526210D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US20120202276A1 (en) 2010-02-26 2012-08-09 Life Technologies Corporation Modified Proteins and Methods of Making and Using Same
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
WO2015089473A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
US9580727B1 (en) * 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
US10624849B2 (en) 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105861485B (zh) * 2016-04-20 2021-08-17 上海伊丽萨生物科技有限公司 一种提高基因置换效率的方法
AU2017263137B2 (en) * 2016-05-13 2021-05-27 Flash Therapeutics Particle for the encapsidation of a genome engineering system
KR102678809B1 (ko) 2017-05-18 2024-06-26 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
CN111328290A (zh) 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
WO2019213257A1 (en) 2018-05-01 2019-11-07 Wake Forest University Health Sciences Lentiviral-based vectors and related systems and methods for eukaryotic gene editing
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
AU2020466994B2 (en) 2019-09-17 2026-05-28 Rutgers, The State University Of New Jersey Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof

Similar Documents

Publication Publication Date Title
KR102455623B1 (ko) CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도
US11479775B2 (en) RNA targeting of mutations via suppressor tRNAs and deaminases
CN113631708B (zh) 编辑rna的方法和组合物
JP7680351B2 (ja) ゲノムを調節するための方法及び組成物
JP2025028917A (ja) 核酸構築物及び使用方法
JP2024099582A (ja) アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法
US20260009027A1 (en) Prime editing-mediated readthrough of premature termination codons (pert)
KR102900462B1 (ko) CRISPR/Cas12f1 시스템 효율화를 위한 U-rich tail을 포함하는 엔지니어링 된 가이드 RNA 및 그 용도
GB2556648A (en) Methods
CN116949012B (zh) 一种融合蛋白及其应用
KR20200135225A (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
KR20230007218A (ko) 초소형 염기교정 시스템 및 이의 용도
WO2024251229A1 (zh) Cas酶及其系统和应用
CA3256516A1 (en) Compositions and methods for modulating a genome in T lymphocytes, induced pluripotent stem cells, and respiratory epithelial cells
KR102151064B1 (ko) 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법
JP2023550381A5 (cg-RX-API-DMAC7.html)
JP2023550381A (ja) 真核生物遺伝子編集のためのベクター、システムおよび方法
KR20250012711A (ko) CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도
JP2025510574A5 (cg-RX-API-DMAC7.html)
CN114395585B (zh) 用于碱基编辑的组合物
JP2025510574A (ja) 真核生物遺伝子編集のための組成物、システムおよび方法
WO2026067648A1 (en) Type ii cas protein and uses thereof
WO2025190256A1 (en) Type ii cas protein and uses thereof
US20230279398A1 (en) Treating human t-cell leukemia virus by gene editing
WO2025049792A1 (en) Compositions and methods for epigenetic regulation of tgfbr2 expression